Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice

Circulation Research

Volumn 114, Issue 1, 2014, Pages 79-91

  Steri, Veronica ^a   Ellison, Tim S ^a   Gontarczyk, Aleksander Maksym ^a   Weilbaecher, Katherine ^b   Schneider, Jochen G ^c   Edwards, Dylan ^a   Fruttiger, Marcus ^d   Hodivala Dilke, Kairbaan M ^e   Robinson, Stephen Douglas ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b WASHINGTON UNIVERSITY   (United States)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

angiogenesis inhibitors; endothelium; integrin V 3; neoplasms

Indexed keywords

BETA3 INTEGRIN; CHEMOKINE RECEPTOR CXCR4; CRE RECOMBINASE; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TIE 1 RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; LUNG ENDOTHELIUM; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 84892931092     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.301591     Document Type: Article

References (47)

1. Nussenbaum F, Herman IM. Tumor angiogenesis: insights and innovations. J Oncol. 2010;2010:132641.
2. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238:491-497.
3. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571.
4. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
5. Van Waes C. Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Head Neck. 1995;17:140-147.
6. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res. 2007;101:570-580.
7. Brooks PC, Strömblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angio-genesis in human skin. J Clin Invest. 1995;96:1815-1822.
8. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes DR Jr, Schwartz RS, Mousa SA. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopon-tin expression during neointima formation. Cardiovasc Res. 1997;36:408-428.
9. Mahabeleshwar GH, Feng W, Phillips DR, Byzova TV. Integrin signaling is critical for pathological angiogenesis. J Exp Med. 2006;203:2495-2507.
10. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002;8:27-34.
11. Reynolds AR, Reynolds LE, Nagel TE, Lively JC, Robinson SD, Hicklin DJ, Bodary SC, Hodivala-Dilke KM. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-defcient mice. Cancer Res. 2004;64:8643-8650.
12. Robinson SD, Reynolds LE, Kostourou V, Reynolds AR, da Silva RG, Tavora B, Baker M, Marshall JF, Hodivala-Dilke KM. Alphav beta3 inte-grin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J Biol Chem. 2009;284:33966-33981.
13. Robinson SD, Hodivala-Dilke KM. The role of beta3-integrins in tumor an-giogenesis: Context is everything. Curr Opin Cell Biol. 2011;23:630-637.
14. Taverna D, Moher H, Crowley D, Borsig L, Varki A, Hynes RO. Increased primary tumor growth in mice null for beta3-or beta3/beta5-integrins or selectins. Proc Natl Acad Sci USA. 2004;101:763-768.
15. Watson AR, Pitchford SC, Reynolds LE, Direkze N, Brittan M, Alison MR, Rankin S, Wright NA, Hodivala-Dilke KM. Defciency of bone marrow beta3-integrin enhances non-functional neovascularization. J Pathol. 2010;220:435-445.
16. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol. 2007;25:1637-1638.
17. Morgan EA, Schneider JG, Baroni TE, Uluçkan O, Heller E, Hurchla MA, Deng H, Floyd D, Berdy A, Prior JL, Piwnica-Worms D, Teitelbaum SL, Ross FP, Weilbaecher KN. Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit. FASEB J. 2010;24:1117-1127.
18. Germain M, De Arcangelis A, Robinson SD, Baker M, Tavora B, D'Amico G, Silva R, Kostourou V, Reynolds LE, Watson A, Jones JL, Georges-Labouesse E, Hodivala-Dilke K. Genetic ablation of the alpha 6-integrin subunit in Tie1Cre mice enhances tumour angiogenesis. J Pathol. 2010;220:370-381.
19. da Silva RG, Tavora B, Robinson SD, et al. Endothelial alpha3beta1-inte-grin represses pathological angiogenesis and sustains endothelial-VEGF. Am J Pathol. 2010;177:1534-1548.
20. Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I, Fruttiger M, Parsons M, Hodivala-Dilke KM. Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med. 2010;2:516-528.
21. Gustafsson E, Brakebusch C, Hietanen K, Fässler R. Tie-1-directed expression of Cre recombinase in endothelial cells of embryoid bodies and transgenic mice. J Cell Sci. 2001;114:671-676.
22. Claxton S, Kostourou V, Jadeja S, Chambon P, Hodivala-Dilke K, Fruttiger M. Effcient, inducible Cre-recombinase activation in vascular endothe-lium. Genesis. 2008;46:74-80.
23. Kostourou V, Lechertier T, Reynolds LE, Lees DM, Baker M, Jones DT, Tavora B, Ramjaun AR, Birdsey GM, Robinson SD, Parsons M, Randi AM, Hart IR, Hodivala-Dilke K. FAK-heterozygous mice display enhanced tumour angiogenesis. Nat Commun. 2013;4:2020.
24. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G, Jones DT, Vojnovic B, Hodivala-Dilke K. Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc. 2012; 7: 89-104.
25. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009;15:392-400.
26. D'Amico G, Robinson SD, Germain M, Reynolds LE, Thomas GJ, Elia G, Saunders G, Fruttiger M, Tybulewicz V, Mavria G, Hodivala-Dilke KM. Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbe-ta3-integrin is absent. PLoS One. 2010;5:e9766.
27. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007;109:1503-1506.
28. Tang Y, Harrington A, Yang X, Friesel RE, Liaw L. The contribution of the Tie2+ lineage to primitive and defnitive hematopoietic cells. Genesis. 2010;48:563-567.
29. Feng W, McCabe NP, Mahabeleshwar GH, Somanath PR, Phillips DR, Byzova TV. The angiogenic response is dictated by beta3 integrin on bone marrow-derived cells. J Cell Biol. 2008;183:1145-1157.
30. Caswell PT, Vadrevu S, Norman JC. Integrins: masters and slaves of endo-cytic transport. Nat Rev Mol Cell Biol. 2009;10:843-853.
31. Zachary I, Rozengurt E. Focal adhesion kinase (p125FAK): a point of convergence in the action of neuropeptides, integrins, and oncogenes. Cell. 1992;71:891-894.
32. Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, Sheppard D, Cheresh DA. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol. 2002;157:149-160.
33. Weis SM, Cheresh DA. Alphav integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med. 2011;1:a006478.
34. Byun HJ, Lee JH, Kim BR, Kang S, Dong SM, Park MS, Lee SH, Park SH, Rho SB. Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway. Microvasc Res. 2012;84:227-234.
35. Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, Gu H, Ng LL, Palmiter RD, Hawrylycz MJ, Jones AR, Lein ES, Zeng H. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci. 2010;13:133-140.
36. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell flopodia. J Cell Biol. 2003;161:1163-1177.
37. Fantin A, Vieira JM, Plein A, Denti L, Fruttiger M, Pollard JW, Ruhrberg C. NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis. Blood. 2013;121:2352-2362.
38. Banerjee D, Harfouche R, Sengupta S. Nanotechnology-mediated targeting of tumor angiogenesis. Vasc Cell. 2011;3:3.
39. Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis. 2003;6:105-119.
40. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M. Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs an-giogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer. 2002;86:788-795.
41. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery. 2006;59:1304-12; discussion 1312.
42. Loges S, Butzal M, Otten J, Schweizer M, Fischer U, Bokemeyer C, Hossfeld DK, Schuch G, Fiedler W. Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochem Biophys Res Commun. 2007;357:1016-1020.
43. Magnon C, Galaup A, Mullan B, Rouffac V, Bouquet C, Bidart JM, Griscelli F, Opolon P, Perricaudet M. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res. 2005;65:4353-4361.
44. Tucker GC. Integrins: molecular targets in cancer therapy. Curr Oncol Rep. 2006;8:96-103.
45. Merck: phase iii trial of cilengitide did not meet primary endpoint in patients with newly diagnosed glioblastoma. February 25, 2013. http://www.drugs. com/clinical-trials/merck-phase-iii-trial-cilengitide-did-not-meet-primary- endpoint-patients-newly-diagnosed-15175.html. Accessed October 29, 2013.
46. Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007;18:1400-1407.
47. Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothe-lial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med. 2011;32:88-111.